#USA #pharmaceuticals #Woburn #Azurity #Covis

Azurity Pharmaceuticals Completes Acquisition of Covis Pharma

On March 14, 2025, Azurity Pharmaceuticals announced the successful completion of its acquisition of Covis Group S.à r.l. With this strategic move, Covis has now become a wholly-owned subsidiary of Azurity, thereby enhancing its position in the pharmaceutical industry.

This acquisition signifies a pivotal growth phase for Azurity, as it seeks to leverage the complementary strengths of both companies across multiple complex dosage forms and therapeutic domains. The amalgamation of resources and expertise is aimed at ameliorating the provision of treatments to neglected patient populations globally.

Strategic Advantages of the Acquisition

The integration presents several strategic benefits that will augment Azurity's capabilities:

1. Expanded Therapeutic Portfolio

The acquisition of Covis enriches Azurity's therapeutic offerings, broadening its portfolio to cover ten complex dosage forms and nine key therapeutic areas, including cardiovascular, respiratory, central nervous system, endocrinology, gastrointestinal, hematology, immunology, anti-infectives, and oncology. This enhancement positions Azurity to better address the diverse needs of healthcare professionals and patients alike.

2. Global Footprint Expansion

With this acquisition, Azurity's global footprint is significantly strengthened. The company will now have a commercial presence in over 50 countries, facilitating easier access to life-changing treatments for patients worldwide. Azurity and its subsidiaries will employ over 800 individuals across North America, Europe, and Asia, further consolidating its position on the global stage.

3. Preferred Biopharmaceutical Partner

The merged entity aspires to become a key partner for global life sciences companies looking to develop and commercialize products. By offering extensive development capabilities and a robust commercial infrastructure, Azurity is set to attract collaborations that will drive innovation in the pharmaceutical sector.

4. Accelerated Innovation

The combination of Azurity's and Covis's expertise sets the stage for accelerated innovation in treatment development. Azurity is committed to its mission of serving overlooked patients by employing a unique and expedited development process that allows for scalability and speed.

5. Next-Generation Business Model

The integrated businesses will benefit from Azurity's cutting-edge business model, which utilizes data analytics and AI-driven capabilities. This innovative approach is designed to enhance stakeholder engagement through optimized omnichannel marketing strategies.

Leadership Insights

Ronald Scarboro, CEO of Azurity, expressed enthusiasm about the acquisition, stating, “We are excited to welcome Covis Pharma into Azurity. The dedication of our teams and our culture of execution allowed us to build this unique and highly differentiated pharmaceutical company together. I look forward to what we will achieve as we grow globally and seize new opportunities driven by our purpose.”

Rajiv De Silva, Chairman of Covis, added, “I am thrilled that Azurity has recognized the achievements and potential of Covis, and I am grateful for the tireless efforts of my colleagues at Covis in supporting patients benefiting from our products. I believe that both companies will be able to leverage their highly complementary capabilities to accelerate the development and commercialization of much-needed medications for underserved patients.”

Support from QHP Capital

Jeff Edwards, Partner at QHP Capital, which holds a majority stake in Azurity, commented, “We are proud to support Azurity in this acquisition, aligning with our commitment to invest in life sciences and healthcare innovations. Our aim is to enhance Azurity's capabilities as it transitions from a small company with limited offerings to a global enterprise with a diverse, high-growth portfolio since our investment in 2018.”

Goldman Sachs served as financial advisor, while Eversheds Sutherland and White & Case acted as legal counsel for Azurity. Guggenheim Securities was the financial advisor for Covis, and Reed Smith and AO Shearman fulfilled the legal advisory roles for Covis.

About Azurity Pharmaceuticals

Azurity Pharmaceuticals is a private company dedicated to providing innovative, high-quality medications to overlooked patients. With a presence in over 50 countries and a diverse portfolio of more than 30 marketed brands, Azurity addresses ten complex dosage forms across nine key therapeutic areas. The company utilizes data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement.

For more information, visit www.azurity.com.

About QHP Capital

QHP Capital invests in technology and service companies within the life sciences, medical technology, and healthcare sectors. The firm has established an investment platform to provide strategic capital and sector expertise in collaboration with strong management teams. For more details, visit www.qhpcapital.com.

Disclosure Notice

Azurity and QHP are not obligated to update or revise forward-looking statements contained in this release based on new information, future events, or evolving circumstances.